Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$0.14 - $12.49 $198 - $17,685
1,416 Added 2.54%
57,111 $8,000
Q3 2022

Nov 14, 2022

BUY
$8.51 - $13.6 $473,964 - $757,452
55,695 New
55,695 $584,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.